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Abstract: The objective of the study was to evaluate oxidative stress (OS) status in 
subjects with different cardiovascular risk factors. With this in mind, we have studied three 
models of high cardiovascular risk: hypertension (HT) with and without metabolic 
syndrome, familial hypercholesterolemia (FH) and familial combined hyperlipidemia 
(FCH) with and without insulin resistance. Oxidative stress markers (oxidized/reduced 
glutathione ratio, 8-oxo-deoxyguanosine and malondialdehide) together with the activity of 
antioxidant enzyme triad (superoxide dismutase, catalase, glutathione peroxidase) and 
activation of both pro-oxidant enzyme (NAPDH oxidase components) and AGTR1 genes, 
as well as antioxidant enzyme genes (CuZn-SOD, CAT, GPX1, GSR, GSS and TXN) were 
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measured in mononuclear cells of controls (n = 20) and patients (n = 90) by assessing 
mRNA levels. Activity of some of these antioxidant enzymes was also tested. An increase 
in OS and pro-oxidant gene mRNA values was observed in patients compared to controls. 
The hypertensive group showed not only the highest OS values, but also the highest  
pro-oxidant activation compared to those observed in the other groups. In addition, in HT a 
significantly reduced antioxidant activity and mRNA induction of antioxidant genes were 
found when compared to controls and the other groups. In FH and FCH, the activation of 
pro-oxidant enzymes was also higher and antioxidant ones lower than in the control group, 
although it did not reach the values obtained in hypertensives. The thioredoxin system was 
more activated in patients as compared to controls, and the highest levels were in 
hypertensives. The increased oxidative status in the presence of cardiovascular risk factors 
is a consequence of both the activation of pro-oxidant mechanisms and the reduction of the 
antioxidant ones. The altered response of the main cytoplasmic antioxidant systems largely 
contributes to OS despite the apparent attempt of the thioredoxin system to control it. 
Keywords: oxidative stress; glutathione peroxidase; superoxide dismutases; mRNA; 
hypertension; familial hypercholesterolemia; combined familial dyslipidemia 
 
1. Introduction  
An excessive production of reactive oxygen species (ROS) outstripping antioxidant defense 
mechanisms has been implicated in conditions which impact the cardiovascular system and the 
development of atherosclerosis [1,2]. An excess of ROS in the blood system as well as in several other 
cellular systems [3], including vascular wall cells [4] and circulating blood cells [5], has been 
described in subjects with advanced atherosclerosis. The increased oxidative stress (OS) is driven by 
the presence of the so-called cardiovascular (CV) risk factors and their impact on both pro-oxidant and 
antioxidant mechanisms. The CV risk factors, hypertension (HT), familial hypercholesterolemia (FH) 
and familial combined dyslipidemia (FHC), which produce and accelerate atherosclerosis also have 
increased OS levels [6–8]. The individual impact on the underlying OS mechanism of each CV risk 
factor, however, is not well known.  
In a previous study carried out in hypertensive patients by our group, we observed that both  
blood and peripheral mononuclear cells exhibit important deficiencies of physiological antioxidants 
with a deep reduction in enzymatic activity and GSH levels [9]. Mechanisms underlying these 
alterations are not well understood, but an increase in activity of pro-oxidant enzymes, mainly NADPH 
oxidase that can be activated by angiotensin II through Angiotensin AT1 receptor (AGTR1) 
stimulation, has been implicated in the high level of ROS in several cellular models of hypertensive 
subjects [10,11]. Likewise, an inadequate response of the main cytoplasmic antioxidant systems has 
been described in studies reported by our group [7]. An increment in pro-oxidant enzyme activity 
increases ROS production, it may saturate the capacity of antioxidant enzymes and leads to high 
generation of OS [12,13]. 
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Whether or not the hyperactivity of the pro-oxidant and a reduction of the antioxidant mechanisms 
observed in hypertensives also exist in the presence of other diseases and CV risk factors has not been 
previously addressed. Thus, the objectives of the present study were to assess OS status, cytoplasmic 
antioxidant enzymatic activity and the activation of pro-oxidant and antioxidant genes in subjects with 
different CV risk factors: HT, FH (model of pure hypercholesterolemia) and FCH (model of mixed 
dyslipidemia) avoiding their overlapping. 
2. Results and Discussion 
2.1. General Characteristics of the Study Population 
The study was performed in 90 patients with CV risk factors (43 HT, 17 FH and 30 FCH) and  
20 control volunteers. Twenty-two of the hypertensives had metabolic syndrome (MS) and 17 of the 
FCH had insulin resistance (IR). The characteristics of each group of patients and controls are shown 
in Table 1 and in Table S2 for patients grouped by MS or IR. Controls were normotensives and had 
slightly lower total-cholesterol levels than hypertensives. In addition, due to selection criteria, the 
controls as well as those with HT had significantly lower levels of total cholesterol or triglycerides 
than did those with FH or with FCH.  
Table 1. General characteristics of the study population. 
Variables  Controls (n = 20) FH (n = 17) FCH (n = 30) HT (n = 43) 
Age (year) 39.9(14.3) 42.6(13.3) 45.6(8.5) 46.3(9.6) 
Gender (M/F)  12/8 3/14 20/10 + 26/17 + 
Body mass index (kg/m2) 25.9(3.0) 25.5(3.6) 26.9(3.9) 30.6(5.1) *,+,Ω 
Office SBP (mmHg) 121.6(11.0) 120.2(10.7) 139.5(5.9) *,+ 157.8(21.3) *,+,Ω 
Office DBP (mmHg) 76.8(5.8) 73.3(9.1) 87.3(4.0) *,+ 99.7(12.7) *,+,Ω 
24-h SBP (mmHg) - - - 142.0(16.9) 
24-h DBP (mmHg) - - - 90.5(10.5) 
Baseline glucose (mg/dL) 89.7(6.4) 88.4(8.9) 101.3(16.4) *,+ 104.3(20.4) *,+  
Total-cholesterol (mg/dL) 189.7(35.9) 304.8(65.7) * 271.9(57.5) * 208.5(33.7) +,Ω 
HDL-cholesterol (mg/dL) 47.6(9.7) 58.1(13.4) * 40.1(9.9) *,+ 44.8(8.9) +,Ω. 
Triglycerides (mg/dL) 102.2(48.6) 127.5(51.9) 294.4(175.1) *,+ 146.2(71.6) Ω 
All values are indicated as mean (standard deviation). All differences are significant after adjusting 
for age, gender and Body Mass Index; * p values denote differences between controls and disease; 
+ p values denote differences between FH and others diseases; Ω p values denote differences 
between FCH and HT. 
2.2. Oxidative Stress and Antioxidant Enzyme Activity 
OS parameters and the antioxidant enzyme activity in the study groups and controls are shown  
in Table 2. Mononuclear cells from HT subjects showed the lowest GSH and the highest GSSG  
values among the control, FH and FCH groups, after adjustment for age, gender and BMI. Likewise,  
8-oxo-dG, a byproduct of ROS-induced DNA damage, was also significantly increased in hypertensive 
subjects as compared to the other groups. The OS degree of FH and FCH, even though it was 
significantly higher than that observed in controls, was lower than that observed in HT. Besides the 
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increment in the oxidative status, there was a significantly lower activity level of the cytoplasmic 
antioxidant enzymes SOD, GPx1 and CAT in HT when compared to that observed in controls and in 
the other two patient groups (Table 2). The reduced activity observed in HT was also present in FH 
and FCH, although the extent of the reduction was significantly lower than that observed in HT.  
In fact, only the activity of GPx1 and CAT was significantly lower in HT than it was in controls.  
The presence of MS in HT group did not increase OS or reduce the antioxidant enzyme activity. 
However, the values of GSSG and GSSG/GSH ratio were higher in the subgroup of IR than non-IR 
subjects in the FCH (Table S2). 
Table 2. Oxidative stress, byproducts and antioxidant enzymes activity in the study. 
Variables Controls (n = 20) FH (n = 17) FCH (n = 30) HT (n = 43) 
GSH 22.9 ± 0.9 18.3 ± 1.1 * 18.7 ± 0.6 * 15.7 ± 0.6 *,Ω 
GSSG 0.28 ± 0.04 0.43 ± 0.04 * 0.32 ± 0.02 + 1.13 ± 0.05 *,+,Ω 
GSSG/GSH 1.3 ± 0.2 2.5 ± 0.3 * 1.8 ± 0.2 * 7.8 ± 0.4 +,Ω 
MDA 0.23 ± 0.02 0.30 ± 0.04 0.26 ± 0.02 0.92 ± 0.29 *,+,Ω 
8-oxo-dG 4.8 ± 0.3 5.5 ± 0.3 5.7 ± 0.2 * 6.8 ± 0.2 *,+,Ω 
Catalase 217.0 ± 10.1 140.2 ± 11.4 * 173.3 ± 10.3 * 110.9 ± 4.5 *,+,Ω 
GPX1 58.5 ± 1.8 54.1 ± 2.1 51.7 ± 1.2 * 32.8 ± 0.9 *,+,Ω 
SOD 6.9 ± 0.6 5.1 ± 0.7 5.6 ± 0.7 3.8 ± 0.3 *,+,Ω 
All values denote mean ± standard error. All differences are significant after adjusting for age, 
gender and Body Mass Index. GSH: reduced glutathione (µmol/mg protein); GSSG: oxidized 
glutathione (µmol/mg protein); MDA: malondialdehide (µmol/mg protein); 8-oxo-dG:  
8-oxo-2'-deoxyguanosine. The value of 8-oxo-dG was expressed as the number of oxidized 
bases/106 deoxyguanosine. Catalase, GPX1 and CuZn-SOD activities were expressed as U/protein 
* p values denote differences between controls and disease. + p values denote differences between 
FH and others disease. Ω p values denote differences between FCH and HT. NOTE: see Table 1  
for comparison. 
2.3. mRNA Levels of Pro-Oxidant Genes 
The mRNA levels of AGTR1 gene and of P22PHOX, P91PHOX, P47PHOX, P67PHOX and RAC1 
genes as components of the NADPH oxidase was analyzed in the mononuclear cells and adjusted for 
age, gender and BMI. As shown in Figure 1a, AGTR1, P67PHOX and P91PHOX mRNA levels were 
significantly higher in HT compared to controls and FCH were higher to controls in P67PHOX and 
P91PHOX mRNA levels. Furthermore, HT with metabolic syndrome displayed the highest values of 
AGTR1 mRNA, Figure 1b. No differences between patients and controls were observed for P22PHOX, 
P47PHOX and RAC1 mRNA levels after adjusting for age, gender and BMI. 
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Figure 1. Angiotensin AT1 receptor (AGTR1) and some components of the NADPH 
oxidase (P91PHOX, P67PHOX) log ratio relative mRNA values in mononuclear cells of 
(a) controls (n = 20, CTL), familial hypercholesterolemia (n = 17, FH), familial combined 
hyperlipidemia (n = 30, FCH) and hypertensives (n = 43, HT); and (b) FCH without insulin 
resistance (n = 13, FCH without IR), FCH with insulin resistance (n = 17, FCH with IR), 
HT without metabolic syndrome (n = 21, HT without MS) and HT with metabolic 
syndrome (n = 22, HT with MS) of the study population. * p values denote differences 
between controls and disease. Statistical tests: Multivariate linear regression analyses 
adjusted by age, gender and BMI. NOTE: A gene is up-regulated when their relative values 
are higher in the disease group than controls. However, if the values are lower ones, the 
gene is down-regulated. 
 
2.4. mRNA Levels of Antioxidant Enzymes 
The mRNA levels of the antioxidant enzymes CAT, GPx1, glutathione peroxidase 4 (phospholipid 
hydroperoxidase) (GPx4), intracellular (SOD1), mitochondrial (SOD2) and extracellular (SOD3)  
Cu-Zn superoxide dismutase and two key enzymes in the synthesis and regeneration of glutathione, 
glutathione synthase (GSS) and glutathione reductase (GSR), are shown in Figure 2. The mRNA levels 
of SOD3, GPX1, GPX4, GSS and GSR mRNAs were significantly lower in patients from the FCH and 
HT groups compared to controls. In patients with FH, only the levels of GPx1 were significantly lower 
than those observed in controls. The presence of metabolic syndrome or insulin resistance did not 
change the results found in the HT or FCH groups except in SOD3, Figure 2. Furthermore, TXN 
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mRNA levels were significantly higher in all groups of patients compared to those for controls, while 
high values of SOD2 and TXN2 were observed only in the HT group, Figures 2 and 3. Finally,  
an increase in TXN and TXN2 mRNA levels were found in HT patients with metabolic syndrome, 
while no differences were found in the FCH subgroups (Figure 3b). 
Figure 2. Log ratio relative mRNA values for (a) catalase (CAT), intracellular (SOD1), 
mitochondrial (SOD2) and extracellular (SOD3) copper zinc superoxide dismutase;  
(b) glutathione peroxidase system (GPX1, GPX4); and (c) some components of the 
glutathione regeneration (GSR, GSS) in mononuclear cells of controls (n = 20, CTL), 
familial hypercholesterolemia (n = 17, FH), familial combined hyperlipidemia (n = 30, 
FCH) and hypertensives (n = 43, HT) and FCH without insulin resistance (n = 13, FCH 
without IR), FCH with insulin resistance (n = 17, FCH with IR), HT without metabolic 
syndrome (n = 21, HT without MS) and HT with metabolic syndrome (n = 22, HT with 
MS) of the study population. * p values denote differences between controls and disease.  
Ψ p values denote differences between Non-IR and IR. Statistical tests: Multivariate linear 
regression analyses adjusted by age, gender and BMI. NOTE: A gene is up-regulated when 
their relative values are higher in the disease group than controls. However, if the values 
are lower ones, the gene is down-regulated. 
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Figure 3. Thioredoxin (TXN) and mitochondrial thioredoxin (TXN2) log ratio relative 
mRNA values in mononuclear cells of (a) controls (n = 20, CTL), familial 
hypercholesterolemia (n = 17, FH), familial combined hyperlipidemia (n = 30, FCH) and 
hypertensives (n = 43, HT); and (b) FCH without insulin resistance (n = 13, FCH without 
IR), FCH with insulin resistance (n = 17, FCH with IR), HT without metabolic syndrome 
(n = 21, HT without MS) and HT with metabolic syndrome (n = 22, HT with MS) of the 
study population. Values are mean (SE). * p values denote differences between controls 
and disease. Ψ p values denote differences between Non-MS and MS. Statistical tests: 
Multivariate linear regression analyses adjusted by age, gender and BMI. NOTE: “without” 
can be abbreviated as “w/o”–HT w/o MS). A gene is up-regulated when their relative 
values are higher in the disease group than controls. However, if the values are lower ones, 
the gene is down-regulated. 
 
2.5. Discussion 
The present study was designed to simultaneously assess the OS levels and the mRNA expression 
of the main antioxidant enzymes and their enzymatic activity in three groups of CV risk patients, HT, 
FH and FCH, in the presence of additional risk factor as MS and IR. A limitation of the study is that 
the HT and FCH groups overlap in the levels of glucose, an important risk factor, but the blood 
pressure is the differential factor between groups. In addition, we have observed that FCH patients 
present higher levels of total cholesterol and triglycerides parameters involved in the modulation of the 
OS. Similarly, the activation of some of the pro-oxidant enzymes was also measured. The three CV 
risk conditions had an increase in OS, although the highest level corresponded to the HT patients. The 
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data from the present study were in agreement with previous reports in which atherosclerosis and 
cardiovascular diseases were associated with reduced GSH [14] and elevated 8-oxo-dG [15,16].  
In addition to the increased OS, antioxidant activity of cytoplasmic enzymes was reduced. The highest 
OS observed in HT was driven by the highest activation of pro-oxidant enzymes and the lowest 
activity of anti-oxidant enzymes. Furthermore, OS is presently accepted as a likely causative factor in 
the development of insulin resistance [17,18]. This is due to prolonged exposure to ROS affects 
transcription of insulin receptor substrate-1 by involving serine/threonine phosphorylation. These data 
are in agreement with the observed increased OS in patients with IR versus non-IR from our study and 
in Martinez-Herbas et al. [6]. Moreover, we have not observed an increase in OS between hypertensive 
subjects with and without MS. However, mRNA levels of the TXN system increased in MS. It is 
known that the main pathogenic mechanism of metabolic syndrome relies on insulin resistance,  
low-level inflammation, and oxidative stress [19] although other factors may influence such as obesity. 
In fact, this is a limitation of our study because the HTA–Non-MS group has a higher percentage of 
obesity greater than the MS subgroup. Consequently, we used a no appropriate control subcohort to 
separate out the contribution of HTA and MS to oxidative stress markers in mononuclear cells. 
The increased OS level was associated with an increment in some of the pro-oxidant mechanisms, 
NADPH oxidase, and to a reduced antioxidant enzyme activity in the cytoplasm. The low enzymatic 
activity of SOD, GPx1 and CAT can be explained partly as a consequence of the modulation of OS on 
antioxidant enzymes and/or an inadequate response. The evidence favoring the existence of an 
inadequate response was supported by the low mRNA levels of the enzymes despite the increased OS. 
The present study was performed in three groups of patients in which the selection criteria allowed 
us to separately study the impact of each risk factor on the OS, avoiding the overlapping of these 
conditions, mainly between HT and FCH. A large number of methods have been used to assess 
oxidative stress in biological systems. The methods used have analyzed the bioavailability of the most 
important antioxidant mechanisms including not only the GSH and GSSG amount, but also the 
enzymatic activity of SOD, CAT and GPx1 together with the OS byproduct 8-oxo-dG and MDA.  
The OS parameters used in these studies were selected based on their recognized value and 
reproducibility [20–23]. We acknowledge that measured OS corresponds to the circulating cells which 
do not necessarily reflect what occurs in the vascular wall, although they also impact the vascular wall. 
Antioxidant enzymes constitute and represent an important part of the total antioxidant activity of 
aerobic cells. The coordination of their functions results in the maintenance of ROS below critical levels 
of incompatibility with cell viability and performance. Every one of these enzymes is susceptible to ROS 
inactivation, and their oxidation leads to a high ratio of degradation of the enzymes by proteosome [24–27]. 
Furthermore, either directly or through derived products, ROS regulates the expression of antioxidant 
genes as a part of an adaptive response [28,29]. In this sense, hydrogen peroxide produces changes in 
SOD3 and SOD1 activity and fatty acid levels can modulate catalase activity [30–36]. 
The mechanisms operating in the OS increment for the three groups of patients showed a similar 
pattern even though their intensities differ. The reduction of antioxidant enzyme activities may result 
from the inactivation of enzymes by increased ROS, an inhibitory mechanism of gene expression 
conditioned by the pathologic milieu or both.  
Up to now, the increased OS has been attributed to the overactivity of mechanisms that increase 
ROS production. Enhanced ROS-induced oxidative stress, which is mainly mediated by superoxide 
Int. J. Mol. Sci. 2011, 12             
 
6154
and hydroxyl radicals, occurs in a wide variety of human and animal hypertension models [37–39],  
HF [40,41] and FCH [6,16,42]. Superoxide, one of the most active ROS in the vascular wall, enhances 
the activity of myeloperoxidase and may activate xanthine oxidase [43]. Furthermore, this radical is 
produced mainly by the hyperactivity of NADPH oxidase, a pro-oxidant enzyme that can be enhanced 
by angiotensin II through the activation of AGTR1. Overactivity of angiotensin II has been described 
not only in hypertension but also in the presence of elevated levels of cholesterol. Indeed, cholesterol 
levels were positively related to the AGTR1 expression in smooth muscle cells. According to this 
hypothesis, we found that in mononuclear cells the increment in OS was accompanied by an increase 
in the expression of AGTR1 and some key components of NADPH oxidase, P91PHOX and P67PHOX. 
The activation of pro-oxidant mechanisms, resulting in ROS overproduction, can reduce the activity of 
the anti-oxidant enzymes as a consequence of enzyme inactivation and induced degradation by its own 
byproducts [44] or other free radicals [45]. 
An alternative explanation for the high OS levels observed, which does not exclude the above, is 
the existence of primary impairment of antioxidant enzymatic activity. The low mRNA levels 
observed, which support this alternative explanation, can only be the result of an impaired expression 
response since no important post-transcriptional or post-translational regulation of these enzymes has 
been described. This impaired expression may result from abnormalities linked to the disease state or 
may be secondary to chronic OS itself. It is well established that ROS regulates the expression of 
antioxidant and many genes as a part of an adaptive response [28,29], although the possibility of 
inducing the suppression of gene response also exists [46,47]. Our previous results showed an 
abnormality in the impact of antihypertensive treatment in OS, enzymatic activity, mRNA values and the 
implication of the xanthine oxidase gene polymorphisms to OS levels and blood pressure [7,48]. In a 
previous study of our group, the low mRNA values were maintained even when the ROS levels 
decrease and the bioavailability of the enzymes was at normal levels. At similar OS levels, mRNA and 
protein SOD were significantly lower in treated hypertensives than in controls [7]. Moreover, the 
downregulation of SOD has been described in other conditions with increased OS, such as in the 
kidney and liver of rats with chronic renal failure induced by renal mass reduction [49]. 
A simultaneous increment in ROS production and the impairment of the response in the main 
antioxidant systems contribute to an increased level of OS with consequences for lipids, proteins and 
DNA. Whether or not treatment for these conditions can reduce OS and normalize the mechanisms 
involved is a matter of debate. In our previous studies, antihypertensive treatment reduced OS, a 
reduction that was greater when treatment was maintained during one year, but the downregulation of 
the mRNA levels was still present. Moreover, the reduction of cholesterol levels lowers OS and 
attenuates pro-atherogenic signaling pathways in a mouse model [50]. Furthermore, the treatment with 
statins and fenofibrate, apart from the improvement in the lipid profile, may increase GPX antioxidant 
capacity [51]. It decreases concentrations of OS and inflammatory markers on diabetes-related 
microvascular diseases [52], increases bioavailability of nitric oxide in atherosclerotic arterial walls 
and activates nitric oxide synthase [53]. In addition, some studies have linked ROS production and OS 
to insulin resistance [54–56]. Through in vitro studies and in animal models of diabetes, it has been 
found that antioxidants improve insulin sensitivity [57,58]. 
In contrast to the abnormalities observed in the main antioxidant mechanisms, the response of the 
thioredoxin system seems to be normal, with an increment in the mRNA levels. In contrast to the GSH 
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system, mRNA levels of the TXN and SOD2 were significantly higher in the hypertensive group than 
in controls. Thioredoxin is a small protein with two isoforms encoded by two different genes, TXN 
and TXN2. Regulation of the GSH and TXN systems seems to be independent, but interaction between 
the two has been described [59]. The disparity observed between the two thiol-systems could be 
explained by the different kind of regulation for each of the systems. The protection mechanism during 
periods of increased oxidative stress, activating the TXN system, would be the presence of such ROS 
as peroxynitrite. It might induce thioredoxin reductase expression in endothelial cells, possibly as a 
protective mechanism during oxidative stress [60]. Furthermore, it is important to note the induction in 
the mRNA levels of SOD2. This enzyme is known to be activated through thioredoxins [61] and have 
an important role played by the cytokine inducible enhancer locus in the Mn-SOD gene. Moreover, 
Mn-SOD is highly regulated at post-translational levels [62]. 
3. Experimental Section 
3.1. Selection of Study Participants 
Patients with HT, FH and FCH were invited to participate if the following criteria were met: (a) for 
hypertension, essential hypertension was defined according to the criteria of the VII Joint National 
Committee [63] and as previously reported [15]; (b) for familial hypercholesterolemia, criteria 
included: plasma levels of total and LDL-C above the 95th percentile corrected for age and sex, 
presence of tendon xanthomata, coronary heart disease in the index patient or in a first-degree relative 
and bimodal distribution of total and LDL-C levels in the family indicating an autosomal dominant 
pattern of phenotype IIa [64]; (c) for FCH, the diagnosis was based on the presence of hyperlipidemia 
(cholesterol and triglyceride concentration above the 90th percentile for our population corrected for 
age and gender) and plasma apo B (>1.20 g/L) in the index patient, together with variable phenotypes 
IIa, IIb or IV in the first degree relatives, a family history of arteriosclerosis and absence of xanthomas 
in the patient and in first degree family members [65]. A group of healthy, normotensive, non-smokers 
were selected as a control group. 
Allocation to one group implies the absence of criteria for pertaining to the other groups, and none 
of the patients were ever treated for the underlying disease or the medication was withdrawn at least 
six weeks before the study, provided that no risk to their health. Subjects were under medical 
supervision throughout the study. 
In addition, HT subjects were subgrouped by the presence or the absence of MS [63]. FCH subjects 
were subgrouped into groups of those with or without IR, as defined by the HOMA index, of higher 
than the 75th percentile of the homeostasis model assessment index (P75th HOMA = 3.2) of our 
population [66]. Those patients with diabetes mellitus were excluded. The Ethics Committee of the 
Hospital approved the study, and the participants gave their informed consent. 
Blood pressure was measured using a mercury sphygmomanometer in the office according to the 
recommendations of the British Hypertension Society [67], and using an oscillometric monitor 
(Spacelabs 90202 or 90207) in ambulatory conditions over 24 h on a regular working day. Blood 
samples were obtained in the morning after a minimum of 8 h fasting. Serum biochemical profiles 
were measured using an autoanalyzer. 
Int. J. Mol. Sci. 2011, 12             
 
6156
3.2. Analytical Procedures 
Markers of oxidative stress were determined in circulating mononuclear cells isolated by  
Ficoll-Hypaque methods as previously reported [68]. Oxidized and reduced glutathione (GSSG and 
GSH) were analyzed by high performance liquid chromatography (HPLC) and GSH was analyzed by 
the glutathione-S-transferase assay [69]. In addition, we calculated as the mean of the GSSG:GSH 
ratios determined in individual subjects. Malondialdehide was analyzed by HPLC and spectrophotometric 
quantification of the MDA-TBA at 532 nm [70]. The protein content was measured using the Bradford 
method. DNA damage, assessed by the formation of 8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxo-dG), 
was quantiﬁed by HPLC-EC detection after its complete enzymatic digestion [71]. Total superoxide 
dismutase activity was determined by spectrophotometry [72] as well as catalase [73] and glutathione 
peroxidase 1 (GPx1) [74] activities. 
3.3. DNA Extraction and 8-oxo-Deoxyguanosine Measurement 
Cell DNA was isolated by means of the Gupta method, with the modification described by  
Muñiz, [71]. In which chloroform isoamyl alcohol (24:1) is used instead of phenol for the removal of 
proteins. Isolated DNA was washed twice with 70% ethanol, dried, and dissolved in 200 μL of  
10 mmol/L Tris/HCl, 0.1 mmol/L EDTA, 100 mmol/L NaCl (pH 7.0) for its enzymatic digestion, as 
previously described [71]. In brief, 5 μg DNA/μL (total DNA, 200 μg) was incubated with 100 U of 
DNase I in 40 μL Tris/HCl (10 mmol/L and 10 μL of 0.5 mol/L MgCl2 (final concentration of  
20 mmol/L) at 37 °C for 1 h. The pH of the reaction mixture was then lowered with 15 μL of sodium 
acetate 0.5 mol/L to pH 5.1. Next, 10 μL of nuclease P1 (5 U) and 30 μL of 10 mmol/L ZnSO4 were 
added to give a final concentration of 1 mmol/L, and the mixture was incubated for 1 h. After 
readjusting the pH with 100 μL of 0.4 mol/L Tris/ClH (pH 7.8) followed by the addition of 20 μL 
alkaline phosphate (3 U), the samples were incubated for 30 min. Enzymes were precipitated with 
acetone (5 vol.), removed by centrifugation, and the supernatant evaporated to dryness. 
DNA hydrolysates were dissolved in HPLC grade water and filtered through a 0.2-μm syringe  
filter before applying the samples to a Waters ODS HPLC column (2.5 × 0.46 ID; 5 μm particle size).  
The amount of 8-oxo-deoxiguanosine (8-oxo-dG) and deoxyguanosine (dG) in the DNA digest was 
measured by electrochemical and UV absorbance detection, under the elution conditions previously 
described [71]. Standard samples of dG and 8-oxo-dG were analyzed to ensure good separation and to 
allow for identification of those derived from cell DNA. 
3.4. mRNA Extraction and Measurement 
Total RNA was extracted from blood mononuclear cells purified by the Ficoll-Hypaque method  
and the Trizol method using a chloroform extraction protocol [75]. One microgram of total RNA was 
treated with DNase I (Roche, Mannheim, Germany) and was reverse-transcribed to cDNA using 
Ready-To-Go You Prime First-Strand beads (Amersham Pharmacia Biotech). Primers for PCR were 
designed by Primer3 program [76] (Table S1). The PCR reaction was done using SYBR Green PCR 
Master Mix and ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, 
CA). To calculate the absolute number of copies, standard curves for each gene were plotted with a 
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quantified cDNA template during each real-time PCR reaction and normalized to average mRNA 
values between glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta 2 microglobulin 
(B2M) as previously described [77]. The mRNA values for each gene analyzed were expressed as the 
log ratio between interest gene mRNA value and the average value of housekeeping gene mRNA. 
Consequently, if the values of the mRNA levels are significantly higher in the groups of patients 
versus controls, it means that the gene is up-regulated. In contrast, if the values of mRNA levels are 
significantly lower in disease groups versus controls, it means that the gene is down-regulated. All the 
mRNA measurements of patients and controls were performed under the same conditions and at the 
same time.  
3.5. Statistical Analysis 
For each variable, the values were expressed as mean ± standard deviation or standard error values 
as indicated. The differences between each of the CV risk factors and the control group were 
calculated using Student t test for continuous variables. Proportions were compared with contingency 
tables and the χ2 test or the Fisher exact test (n > 5). Multivariate linear regression analyses were used 
to estimate the independent contributions of the age, gender and body mass index (BMI) to the mean 
baseline oxidative stress parameters, antioxidant enzyme activities and the relative mRNA levels of 
oxidant and antioxidant genes after log-transformation. Two-tailed values of p < 0.05 were considered 
as statistically significant. 
4. Conclusions 
According to the observed changes in mRNA and the OS level, it can be hypothesized that the GSH 
system plays a larger role than the TXN system does in hypertension. The TXN system is unable to 
control the increased ROS-generation when an inadequate response by the GSH system exists because 
OS is strongly enhanced. The different behavior of the two systems previously described in HT was 
also observed in FH and FCH, although the TXN system seems to be more stimulated in the presence 
of higher OS levels. Such is the case of HT.  
Over the past few years, different reports have suggested that free radical production underlies  
the pathophysiological mechanism of atherosclerosis, proposing an antioxidant intervention to 
ameliorate or prevent it. Strategies focusing on combatting vascular disease through the inhibition of 
superoxide-generating enzymes or by increasing the intake of antioxidant substances have been 
proposed. The possibility that an impaired response of some of the antioxidant mechanisms exists 
offers a new approach for reducing OS. Although the clinical significance of this phenomenon is not 
well understood, it opens the door to a new therapeutic approach to reducing ROS by enhancing the 
antioxidant enzyme expression. Further studies are necessary to delineate the factors involved in the 
disturbance of the regulation of antioxidant enzymes and to point out areas of potential intervention. 
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